INTRODUCTION
============

Non-typhoidal *Salmonella* are among the principal bacterial pathogens implicated in food-borne gastroenteritis worldwide ([@B12]). Antimicrobial agents are not usually required for treatment in salmonellosis but can be lifesaving in cases of severe or systemic infections, as well as treatment for elderly and immunocompromised patients ([@B16]). Multidrug resistance in *Salmonella* has been documented since 1980, a representative class of resistant organisms being the ACSSuT resistance type of *Salmonella typhimurium* DT104, which originated in the UK and spread rapidly to the US and other parts of the world ([@B4]; [@B11]; [@B21]). Hence fluoroquinolones and the extended-spectrum cephalosporins have become the drugs of choice for treatment of acute gastroenteritis caused by *Salmonella* and other enteric pathogens. Resistance toward quinolone and fluoroquinolone antimicrobials is mainly due to target mutations in quinolone resistance determining region (QRDR) of DNA gyrases (*gyrA* and *gyrB*) and Type IV topoisomerases (*parC* and *parE*), which subsequently prevent drugs from binding ([@B15]). Although high level fluoroquinolone-resistant *Salmonella* are known to be associated with specific serotypes of *Salmonella* and have been reported in scattered regions around the world, their prevalence remains low. This is probably due to the fact that the process of selection of double *gyrA* and single *parC* mutations is not very efficient. Nevertheless, several lines of evidence have suggested that emergence of multidrug resistant non-typhoidal *Salmonella* strains has significant impact on the effectiveness of current strategies, including reduced efficacy of early empirical treatment to control and manage diseases associated with food-borne infections. These include reduced efficacy of early empirical treatment as well as limited choice of treatment.

Plasmid mediated quinolone resistance (PMQR) genes such as *qnrA, qnrB, qnrC, qnrD, qnrS, qepA,* and *aac(6′)Ib-cr* have been increasingly reported in bacterial pathogens. The *qnr* type PMQR genes bind to DNA gyrase and topoisomerase to block the action of fluoroquinolones resulting in reduced susceptibility to fluoroquinolones ([@B27]). QepA encodes a MFS-type eﬄux pump which is able to excrete quinolone into extracelluar space ([@B31]). AAC(6′)Ib-cr acetylates ciprofloxacin (CIP) and norfloxacin ([@B24]). It is postulated that these PMQR genes are able to contribute to the development of quinolone resistance in these organisms ([@B2]). Recently, a novel transmissible resistance-nodulation-division (RND) eﬄux pump OqxAB, which mediated resistance to olaquindox, chloramphenicol, nalidixic acid, and elevated minimal inhibitory concentrations (MICs) of other antimicrobial reagents including ampicillin, gentamicin, and CIP (MIC between 0.06 and 0.25 μg/ml), has been identified ([@B13]). OqxAB was encoded on an IncXI plasmid, pOLA52, harbored by a swine *Escherichia coli* isolate ([@B14]). More recently, OqxAB was reported to be prevalent in organisms isolated from pork and pig farms in China ([@B33]; [@B20]; [@B28]), as well as from human food (18). On the other hand, the *oqxAB* gene has not been found in clinical isolates until recently, when it became detectable in clinical strains of *E. coli*, *Salmonella,* and *Klebsiella pneumoniae* ([@B18]; [@B23]; [@B25]; [@B32]). The functional and clinical significance of this and other PMQR genes such as *qnrA, B, D,* and *S*, which have also become prevalent in clinical *Salmonella* isolates ([@B3]; [@B7]; [@B19]), remains unclear.

We have previously characterized 239 human clinical *S. typhimurium* isolates recovered from hospital patients in Hong Kong during the period of 2005--2011 for their susceptibilities to fluoroquinolones and other antibiotics and the prevalence of PMQR genes. Two PMQR genes, *oqxAB* and *aac(6′)Ib-cr*, were found to exhibit close relationship with fluoroquinolone resistance in *S. typhimurium*. Approximately 44% of the *oqxAB*-positive *S. typhimurium* were resistant to CIP and around 89% of *oqxAB*, *aac(6*′*)Ib-cr-*positive isolates were resistant to CIP, while only 11% of the *oqxAB*-negative isolates were resistant to CIP ([@B30]). In the current study, we want to investigate the direct association of *oqxAB/aac(6*′*)Ib-cr* with the development of fluoroquinolone resistance in *S. typhimurium*. We confirm that *oqxAB* and *aac(6*′*)Ib-cr* can mediate rapid development of fluoroquinolone resistance in *S. typhimurium* and could be a contributive factors accounting for the increasing prevalence of fluoroquinolone-resistant *Salmonella* in Hong Kong in recent years.

MATERIALS AND METHODS {#s1}
=====================

BACTERIAL STRAINS
-----------------

239 *S. typhimurium* previously described clinical isolates were included in this study ([@B30]).

PCR AND TARGET GENE MUTATION SCREENING IN *S. typhimurium*
----------------------------------------------------------

The QRDRs of *gyrA* and *parC* were amplified by PCR as previously described ([@B5]), followed by determination of their nucleotide sequences and comparison to the wild-type *S. typhimurium* LT2 strain to identify target gene mutations in the test strains. The *gyrA* and *parC* sequences of four *Salmonella* isolates, S08-52, S10-9, S05-23, and S05-30, were submitted to GenBank with the accession numbers for *gyrA*, KM504240, KM504241, KM504242, and KM504243 and *parC*, KM513651, KM513652, KM513653, and KM513654. The association of Insertion sequence IS*26* with *oqxAB* was determined by PCR using primers IS*26-*F(5′GCTGTTACGACGGGAGGAG) and oqx-R (5′ GGAGACGAGGTTGGTATGGA).

CONJUGATION EXPERIMENTS
-----------------------

A conjugative experiment was carried out as previously described ([@B17]) using sodium azide-resistant *E. coli* J53 strain as recipient. Briefly, overnight culture of donor and recipient strains were mixed and collected on a filter, which was subjected to overnight incubation on a blood agar plate. The mixture was then spread on double selective blood agar plates containing olaquindox (128 μg/ml) and sodium azide (100 μg/ml).

S1-PFGE AND HYBRIDIZATION
-------------------------

S1-PFGE was conducted to determine the size of large plasmids. Briefly, agarose-embedded DNA was digested with S1 nuclease (New England BioLab) at 37°C for 1 h. The restriction fragments were separated by electrophoresis in 0.5 Tris-borate-EDTA buffer at 14°C for 18 h using a Chef Mapper electrophoresis system (Bio-Rad, Hercules, CA, USA) with pulse times of 2.16 to 63.8 s. Phage Lambda PFGE ladder (New England BioLab) was used as DNA size marker. The gels were stained with GelRed, and DNA bands were visualized with UV transillumination (Bio-Rad). Chromosomal and plasmid DNA of *S. typhimurium* strains were transferred and cross-linked onto nylon membrane and hybridized with a DIG-labeled *oqxAB* probe using DIG High Prime DNA Labeling and Detection Starter Kit I (Roche) following manufacturer's instructions to determine the localization of *oqxAB* and *aac(6*′*)-Ib-cr* genes in *S. typhimurium* genetic materials.

*oqxAB* CLONING, PLASMID TRANSFORMATION, AND PLASMID CURING
-----------------------------------------------------------

Cloning of *oqxAB* into pTrcHisB (Life Technologies) vector was done by PCR using primers pTrc-oqxAB-F (5′TTACTACTCGAGAATGAGCCTGCAAAAAAC) and pTrcoqxAB-R (5′AGGATCGAATTCCTAGGCGGGCAGATCCTC). pTrc-*oqxAB* was transformed into *S. typhimurium* LT2. Plasmids from clinical strains were extracted by Qiagen Mini-prep kit, electroporated into *S. typhimurium* LT2 and a nalidixic acid and CIP susceptible *S. typhimurium* clinical strain 11--28, and selected on plates containing 32 μg/ml olaquindox. Plasmid curing was performed on clinical *S. typhimurium* strain 10--63 as previously described with slight modification ([@B26]). The strain was grown in 3 ml LB at 43°C for 2 weeks and selected on plates containing 0, 8, 16, 32 μg/ml olaquindox.

MUTATION PREVENTION CONCENTRATION (MPC)
---------------------------------------

Mutation prevention concentration (MPC) of *oqxAB*, *aac(6*′*)Ib-cr* positive, and negative strains was determined as described previously ([@B9], [@B10]). Briefly, MPC was determined by spreading 1 × 10^9^ cells on LB agar plates containing a range of concentration of CIP: 0, 0.05, 0.1, 0.25, 0.5, 1, 2, 4, 8, 16, 32 μg/ml. Plates containing CIP were incubated for up to 72 h, whereas CIP-free plates were incubated for 24 h. Viable counts on each plate were recorded. MPC was defined as the lowest antibiotic concentration at which no colonies were observed. For each strain, MPC was determined on the basis of the results of at least three independent experiments.

RESULTS
=======

PMQRS AND SINGLE GyrA MUTATION MEDIATE DEVELOPMENT OF FLUOROQUINOLONE RESISTANCE IN *S. typhimurium*
----------------------------------------------------------------------------------------------------

To determine if *oqxAB* alone or the combination of *oqxAB* and *aac(6*′*)Ib-cr* can contribute to fluoroquinolone resistance, the effect of interplay between *oqxAB*, *aac(6*′*)Ib-cr,* and target mutations in mediating fluoroquinolone resistance phenotypes in *Salmonella* was studied. Among all *oqxAB* negative *S. typhimurium* organisms, the vast majority of those which exhibited CIP MIC ≤0.05 μg/ml had no mutation in the *gyrA* and *parC* genes. Single amino acid substitution (D87Y or D87N) in GyrA was often detected in strains with CIP MIC between 0.1 and 1 μg/ml. Interestingly, two CIP-resistant isolates (CIP MIC = 1 μg/ml) showed only single mutation at D87Y. Double substitution in GyrA (S83F and D87Y or N) and a single substitution in ParC (S80I) were consistently detected in those with CIP MIC ≥2 μg/ml (**Table [1](#T1){ref-type="table"}**). Among all *oqxAB* positive *S. typhimurium* strains, no mutation was detected in *gyrA* and *parC* in strains with CIP MIC ≤0.05 μg/ml; single mutation in GyrA (D87Y or D87N), but not in ParC, was detected in strains whose CIP MIC was between 0.25 and 2 μg/ml. Among all isolates which were positive to both *oqxAB* and *aac(6*′*)Ib-cr*, single mutation in GyrA (D87Y or D87N), but not in ParC, was detected in strains whose CIP MIC was between 0.25 and 2 μg/ml, whereas most of the strains from this category exhibited CIP MIC ≥1 μg/ml. Comparative analysis of mutational and drug susceptibility data of *oqxAB* negative, *oqxAB* positive, and *oqxAB*, *aac(6*′*)Ib-cr* positive strains showed that similar mutational profiles could result in drastically different CIP MIC, depending on whether the organism harbored the *oqxAB* or *oqxAB, aac(6*′*)Ib-cr* genes. Strikingly, simultaneous presence of a single *gyrA* mutation and *oqxAB*, or both *oqxAB* and *aac(6*′*)Ib-cr* genes, was sufficient to produce CIP resistance (CIP MIC = 1 μg/ml); however, double mutations in *gyrA* plus a single mutation in *parC* were required to mediate CIP MIC ≥2 μg/ml when *oqxAB* was absent. Importantly, around 98% of *oqxAB* positive *S. typhimurium* strains harbored mutations in the *gyrA* or *parC* genes, whereas less than 60% of *oqxAB* negative *S. typhimurium* strains had mutations in either or both of these two genes (Data not shown). Taken together, these findings suggest that acquisition of *oqxAB* or *oqxAB*, *aac(6*′*)Ib-cr* by *S. typhimurium* could mediate selection of fluoroquinolone resistance in *S. typhimurium*.

###### 

Presence of target mutations in different level of ciprofloxacin MIC of *oqxAB* positive and negative *Salmonella typhimurium* isolates.

  CIP MIC   Clinical *S. typhimurium*                                                                 
  --------- --------------------------- ------------ --------- ---- ----------- ---- ---- ----------- ----
  ≤0.05     104                         WT/D87N      WT/S80R   1    WT          WT   0                
  0.1       24                          D87N         WT        0                     2    WT          WT
  0.25      14                          D87N         WT        1    D87Y        WT   1    D87Y        WT
  0.5       18                          D87N         WT        3    D87Y        WT   3    D87Y        WT
  1         2                           D87Y         WT        2    D87Y        WT   6    D87Y        WT
  2         2                           S83F, D87G   S80R      3    D87Y/D87N   WT   35   D87Y/D87N   WT
  4         0                                                  0                     10   D87Y        WT
  8         0                                                  0                     0                
  ≥16       8                           S83F, D87G   S80R      0                     0                
  Total     172                                                10                    57               

TRANSFERABILITY AND GENETIC LOCATION OF *oqxAB*
-----------------------------------------------

Thirty randomly selected *oqxAB* positive *S. typhimurium* isolates were subjected to conjugation experiment to determine the transferability of the *oqxAB* gene that they harbored. Surprisingly, none of the *S. typhimurium* strains tested was able to transfer this resistance element to *E. coli* J53 recipient strain through conjugation. S1-PFGE and Southern hybridization were performed on four *S. typhimurium* isolates and it showed that *oqxAB* and *aac(6*′*)Ib-cr* were concurrently present on plasmids of various sizes in these *S. typhimurium* isolates, hybridization results of two of which were shown in **Figure [1](#F1){ref-type="fig"}**. In all the tested *S. typhimurium* isolates, the *oqxAB* gene was found to be flanked by the IS*26* fragment in a manner similar to that of the pOLA52 plasmid as previously reported ([@B22]), suggesting that the *oqxAB* gene that was becoming prevalent in *S. typhimurium* could have been derived from the original transferable element located in pOLA52. To test this possibility, we performed PCR screening to determine if pOLA52 specific DNA sequences were prevalent among the test plasmids. To our surprise, however, none of the plasmids that carried *oqxAB* and *aac(6*′*)Ib-cr* contained such sequences of pOLA52 (Data not shown).

![**S1-PFGE and southern hybridization of 16SrRNA, *oqxA*, and *aac(6*′*)Ib-cr* on two oqxAB-positive isolates.** Arrows indicated chromosomal DNA or plasmids harboring *oqxAB* and *aac(6*′*)Ib-cr*. 06--53 and 10--63 are *oqxAB*-positive *S. typhimurium* clinical isolates; M, Lambda PFGE marker.](fmicb-05-00521-g001){#F1}

CONTRIBUTION OF *oqxAB* AND *aac(6*′*)Ib-cr* TO THE ELEVATED CIPROFLOXACIN MIC IN *S. typhimurium*
--------------------------------------------------------------------------------------------------

To directly prove the degree of contribution of *oqxAB* and *aac(6*′*)Ib-cr* to the development of fluoroquinolone resistance in *S. typhimurium*, *oqxAB* was cloned into a pTrc expression vector and transformed into *S. typhimurium* LT2 strain. Compared to the original *oqxAB* negative *S. typhimurium* LT2 strain, pTrc-*oqxAB-* carrying *S. typhimurium* LT2 exhibited a CIP MIC of 0.25 μg/ml, with a 20-fold increase. However, *S. typhimurium* LT2 carrying pTrc-*oqxAB* showed much weaker growth than its parental counterpart, which was presumably due to the fitness cost caused by the over-expression of *oqxAB* in the host strain. To overcome this problem, the plasmids that carried *oqxAB* and *aac(6*′*)Ib-cr* were extracted from different clinical *S. typhimurium* isolates and electroporated into *S. typhimurium* LT2 with no success. The plasmids were then electroporated into an *oqxAB*-negative *S. typhimurium* strain 11--28. Upon acquisition of such plasmid, the CIP MIC of this *S. typhimurium* strain increased by approximately fourfold (**Table [2](#T2){ref-type="table"}**). To further prove the contribution of *oqxAB* and *aac(6*′*)Ib-cr* to *S. typhimurium* fluoroquinolone resistance, the plasmid carrying such genes in a clinical *S. typhimurium* strain 10--63 was cured and it showed that the curing of the plasmid in 10--63 decreased the CIP MIC by approximately fourfold (**Table [2](#T2){ref-type="table"}**). Taken together, our data had proven that *oqxAB* and *aac(6*′*)Ib-cr* contributed to about four fold increase of CIP MIC in *S. typhimurium*. The MICs of other antibiotics were also determined for *S. typhimurium* that acquired *oqxAB*, *aac(6*′*)Ib-cr* encoding plasmids. In addition, it is showed that acquisition of *oqxAB* and *aac(6*′*)Ib-cr* encoding plasmids ensured resistance to ampicillin, chloramphenicol, streptomycin, nalidixic acid, sulfamethoxazole, tetracycline, trimethoprim, and olaquindox in addition to the elevated CIP MIC (**Table [2](#T2){ref-type="table"}**). This is also consistent to our previous finding that the presence of *oqxAB* in *S. typhimurium* was associated with the ACSSuT R phenotype. As much as 56% of *oqxAB*-positive *S. typhimurium* clinical isolates were resistant to ACSSuT, whereas only 14% of *oqxAB*-negative isolates were resistant to ACSSuT ([@B30]).

###### 

MIC profiles for *Salmonella* strains with various *oqxAB* and *aac(6*′*)Ib-cr* -borne plasmids.

  Strain      MIC (μg/ml)                                                                
  ----------- ------------- ---- ------- ------ ---- ------ ------- ---- ---- ---- ----- ------
  11--28\*    ≤4            ≤1   0.012   4      2    ≤4     ≤128    ≤4   ≤4   ≤1   8     8
  P06--57\#   ≥128          ≤1   0.05    16     64   ≥128   ≥1024   32   ≤4   32   128   ≥128
  P07--43\#   ≥128          ≤1   0.05    32     64   ≥128   ≥1024   32   ≤4   32   64    ≥128
  P08--11\#   ≥128          ≤1   0.05    16     64   ≥128   ≥1024   32   ≤4   32   64    ≥128
  P10--9\#    ≥128          ≤1   0.05    16     64   ≥128   ≥1024   32   ≤4   32   128   ≥128
  10--63\*    ≥128          ≤1   1       ≥128   64   ≥128   ≥1024   32   ≤4   ≤1   512   32
  10--63C     16            ≤1   0.25    ≥128   2    ≥128   ≥1024   ≤4   ≤4   ≤1   16    8

AMP, ampicillin; CRO, ceftriaxone; CIP, ciprofloxacin; NA, Nalidixic acid; TET, tetracycline; CHL, chloramphenicol; SUL, sulfamethoxazole; TRI, trimethoprim; AMK, amikacin; GEN, gentamicin; STE, streptomycin; OLA, olaquindox.
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CONTRIBUTION OF *oqxAB* AND *aac(6*′*)Ib-cr* TO ELEVATED MPC OF FLUOROQUINOLONE IN *S. typhimurium*
---------------------------------------------------------------------------------------------------

To validate the hypothesis that *oqxAB* and *aac(6*′*)Ib-cr* contributed to mutation development, MPC of CIP were determined for *S. typhimurium* with and without *oqxAB*. As shown in **Table [3](#T3){ref-type="table"}**, *oqxAB, aac(6*′*)Ib*-*cr* positive clinical *Salmonella* isolates, 06--57, 07--43, and 08--11 exhibited much higher MPC of CIP than the *oqxAB, aac(6*′*)Ib*-*cr*-negative *Salmonella* strains, 05--41, 07--54, and 10--25 (**Table [3](#T3){ref-type="table"}**). Furthermore, although *Salmonella* 11--28 strain exhibited MPC for CIP of about 0.1 μg/ml, transformation of plasmids from other clinical *Salmonella* isolates carrying *oqxAB*, *aac(6*′*)Ib*-*cr* to *Salmonella* 11--28 dramatically increased its MPC to 2∼4 μg/ml. On the other hand, *Salmonella* 10--63 exhibited MPC of 8 μg/ml, yet the curing of the *oqxAB*, *aac(6*′*)Ib*-*cr* encoding plasmid led to a slightly decreased MPC (4 μg/ml). The minimal effect of curing of *oqxAB*, *aac(6*′*)Ib*-*cr* encoding plasmid on the MPC of 10--63 may be due to the fact that the long-term starvation stress used to cure the plasmid may have caused stress response to develop in the isolate, thereby indirectly contributing to the elevated MPC for strain.

###### 

MICs of nalidixic acid (NA) and ciprofloxacin (CIP) and mutation prevention concentration (MPC) toward CIP of *Salmonella* isolates with various background of *oqxAB* and *aac(6*′*)Ib-cr*.

  *Salmonella* Isolate   *oqxAB*,*aac(6*′*)Ib-cr*   QRDR Mutations   MIC (μg/ml)   MPC (μg/ml)   GyrA mutation^†^   MPC/MIC          
  ---------------------- -------------------------- ---------------- ------------- ------------- ------------------ --------- ------ ----
  06--57\*               \+                         WT               WT            32            0.1                2         NT     20
  07--43\*               \+                         WT               WT            16            0.05               0.5       NT     10
  08--11\*               \+                         WT               WT            32            0.1                1         NT     10
  05--41\*               --                         D87N             WT            32            0.025              0.1       NT     4
  07--54\*               --                         WT               WT            16            0.012              0.1       NT     8
  10--25\*               --                         WT               WT            4             0.025              0.1       NT     4
  11--28\*               --                         WT               WT            4             0.012              0.1       WT     8
  p06--57\#              \+                         WT               WT            16            0.05               4         D87N   80
  p07--43\#              \+                         WT               WT            32            0.05               2         WT     40
  p08--11\#              \+                         WT               WT            16            0.05               2         D87G   40
  p10--9\#               \+                         WT               WT            16            0.05               2         WT     40
  10--63\*               \+                         D87N             WT            ≥128          1                  8         D87Y   8
  10--63c                --                         D87N             WT            ≥128          0.25               4         D87Y   16

NA, Nalidixic acid; CIP, ciprofloxacin.
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Ten to 63 C. It has been shown that long-term starvation stress stimulates the stringent SOS response in bacteria, which is essential in bacteria for acquisition of mutations leading to resistance to some antibiotic drugs ([@B8]). Most importantly, compared to *Salmonella* 11--28 alone, which did not develop *gyrA* mutation in MPC assay, *Salmonella* 11--28 transformed with *oqxAB*, *aac(6*′*)Ib*-cr encoding plasmids from *Salmonella* 06--57 and 08--11 developed single mutation in *gyrA*, which may partly contributed to the increase of CIP MPC (**Table [3](#T3){ref-type="table"}**). It is probably due to that the presence of *oqxAB* and *aac(6*′*)Ib*-cr may enable *S. typhimurium* to survive under fluoroquinolone stress and facilitate subsequent development of target mutations. Nevertheless, these data confirm that *oqxAB, aac(6*′*)Ib*-*cr* plays a key role in elevated CIP MIC and MPC, and hence resistance to fluoroquinolone in *S. typhimurium*.

DISCUSSION
==========

An important finding in this work is that the *oqxAB* and *aac(6*′*)Ib-cr* gene products not only directly contribute to the elevated CIP MIC, but also enhance the ability of *S. typhimurium* to survive in an environment with high dose of CIP, which may in turn facilitate the development of fluoroquinolone resistance. The mechanism of fluoroquinolone resistance in *Salmonella* has conventionally been attributed to double mutations in *gyrA* with or without a single *parC* mutation ([@B1]; [@B6]). Unlike *E. coli* and *Campylobacter*, double *gyrA* mutations in *Salmonella* were rare and presumably difficult to acquire, therefore fluoroquinolone remained an effective treatment of choice for severe *Salmonella* infections. In this study, we demonstrated that acquisition of the *oqxAB or oqxAB, aac(6*′*)Ib-cr* genes in *S. typhimurium*, could mediate development of resistance to CIP (CIP MIC ≥1 μg/ml). We postulate that the pump activities and enzymatic hydrolysis of fluoroquinolones enable the organisms to withstand antibiotic pressure for a prolonged period, during which mutational changes can occur. Elevation of the antibiotic resistance potential of *Salmonella* is one way by which *oqxAB* can help the host strain to successfully launch clinical infection in human, leading to a dramatic increase in the proportion of *oqxAB* positive strains observable among clinical *Salmonella* isolates recovered in recent years ([@B29]). The increased prevalence of *oqxAB* positive *S. typhimurium* in clinical isolates also contributes directly to a higher percentage of fluoroquinolone resistance in clinical salmonella strains. In 2011, the proportion of the *oqxAB* positive *S. typhimurium* in Hong Kong that were found to be resistant to CIP reached 34% (Data not shown).

The fact that *oqxAB* could not be found in *S. typhimurium* until 2006 may be due to its poor ability to replicate in *Salmonella* initially; this notion is supported by the fact that transformation of *oqxAB*-borne plasmid to *S. typhimurium* did not elevate MIC of CIP in these strains and that direct expression of *oqxAB* into *S. typhimurium* had a fitness cost in this work ([@B13]; [@B30]). Nevertheless, our data indicate that the *oqxAB* gene has adapted to co-exist in *S. typhimurium*. In this study, *oqxAB* were found to be associated with IS*26* but not carried by pOLA52-like plasmids, suggesting *oqxAB* was excised from pOLA52 and integrated into other plasmids mediated by IS*26* transposase. Since no *oqxAB* encoding plasmid in *Salmonella* has been sequenced, the mechanism underlying the co-existence of *oqxAB* and *aac(6*′*)Ib-cr* in over 80% of the *oqxAB*-positive strain is not clear. The quick expansion of *oqxAB* and *aac(6*′*)Ib-cr* positive, CIP-resistant *S. typhimurium* will pose huge threat to efforts of infection control of *Salmonella* infections. Urgent actions are required to halt further transmission of the *oqxAB* positive strains in both environmental and clinical settings. In addition, it remains to be seen if *oqxAB* has been taken up by other bacterial species and whether it plays a role in the evolution of resistance and virulence traits of various bacterial pathogens. Findings in this work also highlight a need to investigate the impact of *oqxAB* in a wide range of foodborne and zoonotic pathogens.
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